Sagopilone
- Generic Name
- Sagopilone
- Drug Type
- Small Molecule
- Chemical Formula
- C30H41NO6S
- CAS Number
- 305841-29-6
- Unique Ingredient Identifier
- KY72JU32FO
- Background
Sagopilone has been used in trials studying the treatment of Melanoma, Neoplasms, CNS Disease, Breast Cancer, and Breast Neoplasms, among others. It is a so-called fully synthetic epothilone and is the first such compound to be in clinical development to combat several forms of cancer. Epothilones are 16-member ring macrolides with antimicrotubule activity that share a similar mechanism of action to the taxanes but have demonstrated potent antiproliferative activity in several different multidrug-resistant and paclitaxel-resistant tumor cell lines in vitro and in vivo.
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
- Conditions
- Ovarian CancerProstate Cancer
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00751205
Phase II Trial Of ZK-EPO (ZK 219477) (Sagopilone) In Metastatic Melanoma
- First Posted Date
- 2008-01-22
- Last Posted Date
- 2013-12-11
- Target Recruit Count
- 35
- Registration Number
- NCT00598507
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
ZK219477 (Sagopilone) in Patients With Breast Cancer and Brain Metastases
- First Posted Date
- 2007-07-04
- Last Posted Date
- 2013-03-14
- Lead Sponsor
- Nancy Lin, MD
- Target Recruit Count
- 15
- Registration Number
- NCT00496379
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Investigation of Mass Balance of the Test Drug and Major Metabolites
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2015-12-14
- Lead Sponsor
- Bayer
- Target Recruit Count
- 7
- Registration Number
- NCT00432302
Epothilone ZK-219477 in Treating Patients With Recurrent Glioblastoma
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2012-09-24
- Target Recruit Count
- 38
- Registration Number
- NCT00424060
- Locations
- 🇨ðŸ‡
Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
Epothilone in Recurrent Glioblastoma Patients
- First Posted Date
- 2006-11-08
- Last Posted Date
- 2014-04-17
- Lead Sponsor
- Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
- Target Recruit Count
- 15
- Registration Number
- NCT00397072
- Locations
- 🇮🇹
Istituto Nazionale Neurologico, Milan, Italy
A Study of a New Chemotherapy Agent in Combination With Cisplatin to Treat Small Cell Lung Cancer
- Conditions
- Carcinoma, Small Cell
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 26
- Registration Number
- NCT00359359
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
- First Posted Date
- 2006-07-10
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 53
- Registration Number
- NCT00350051
ZK-Epo Given With Carboplatin in Patients With Recurrent Ovarian Cancer
- First Posted Date
- 2006-05-12
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 45
- Registration Number
- NCT00325351
Evaluation of a New Agent for Treatment of Advanced Stage Breast Cancer
- First Posted Date
- 2006-04-12
- Last Posted Date
- 2015-12-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 65
- Registration Number
- NCT00313248
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.